Chamberlain College of Nursing - NR 511NR511-Final Exam Study Guide

NR511 Final Exam Study Guide See Midterm and Week 1 Study Guide for content covering weeks 1, 2 & 3 Common Infections 1. Impetigo Impetigo is a superficial bacterial infection of the skin. It is classified into prim ...

NR511 Final Exam Study Guide See Midterm and Week 1 Study Guide for content covering weeks 1, 2 & 3 Common Infections 1. Impetigo Impetigo is a superficial bacterial infection of the skin. It is classified into primary impetigo when there is a direct bacterial invasion of previously normal skin or secondary impetigo when the infection arises at sites of minor skin trauma. The occurrence of secondary impetigo is referred to as impetiginization. Impetigo is most frequently observed in children ages 2–5 years of age, although older children of any age and adults may also be affected. The infection usually occurs in warm, humid conditions and is easily spread among individuals in close contact. Risk factors include poverty, crowding, poor hygiene, and underlying scabies. Impetigo is primarily caused by S. aureus. Group A Streptococcus (GAS) causes a minority of cases, either alone or in combination with S. aureus. Occasionally, MRSA is detected in some cases of impetigo. Variants of impetigo include nonbullous impetigo, bullous impetigo, and ecthyma. • Nonbullous impetigo—most common form of impetigo and begins as papules that progress to vesicles surrounded by erythema. Within a week, the papules eventually become pustules that enlarge, break down, and form thick, adherent crusts with a characteristic golden appearance. Lesions usually involve the face and extremities. Regional lymphadenitis may occur, although systemic symptoms are usually absent. • Bullous impetigo—Bullous impetigo is seen primarily in young children in which the vesicles enlarge to form flaccid bullae with clear yellow fluid, which later becomes darker and ruptures, leaving a thin brown crust. The trunk is more frequently affected. Bullous impetigo in an adult with appropriate demographic risk factors should prompt an investigation for previously undiagnosed human immunodeficiency virus (HIV) infection. • Ecthyma—This form of impetigo, caused by group A, beta-hemolytic Streptococcus (Streptococcus pyogenes), consists of an ulcerative form in which the lesions extend through the epidermis and deep into the dermis. Ecthyma resembles "punched-out" ulcers covered with yellow crust surrounded by raised violaceous margins. Poststreptococcal glomerulonephritis is a serious complication of impetigo (ecthyma). This condition develops within 1–2 weeks following infection. Poststreptococcal glomerulonephritis manifests with edema, hypertension, fever, and hematuria. The diagnosis of impetigo often can be made on the basis of clinical manifestations. A Gram stain and culture of pus or exudate is recommended to identify whether S. aureus and/or a beta-hemolytic Streptococcus is the cause. However, treatment may be initiated without these studies in patients with typical clinical presentations. Bullous and nonbullous impetigo can be treated with either topical or oral therapy. Topical therapy is used for patients with limited skin involvement whereas oral therapy is recommended for patients with numerous lesions. Unlike impetigo, ecthyma should always be treated with oral therapy. Benefits of topical therapy include fewer side effects and lower risk for contributing to bacterial resistance compared with oral therapy. Topical choices to treat impetigo include the following medications for 5 days. • Mupirocin three times daily • Retapamulin twice daily Extensive impetigo and ecthyma should be treated with an antibiotic effective for both S. aureus and streptococcal infections unless cultures reveal only streptococci. Dicloxacillin and cephalexin are appropriate treatments. A 7-day course of oral antibiotic treatment is recommended. If only streptococci are detected in extensive impetigo or ecthyma, oral penicillin is the preferred therapy. MRSA impetigo can be treated with doxycycline, clindamycin, or trimethoprimsulfamethoxazole (Bactrim). Crusted lesions can be washed gently. Children can return to school 24 hours after beginning an effective antimicrobial therapy. Draining lesions should be kept covered. Quiz: Sally, aged 25, presents with impetigo that has been diagnosed as infected with staphylococcus. The clinical presentation is pruritic tender, red vesicles surrounded by erythema with a rash that is ulcerating. She has not been adequately treated recently. Which type of impetigo is this? a. Bullous impetigo b. Staphylococcal scalded skin syndrome (SSSS) c. Nonbullous impetigo d. Ecthyma 2. Staphylococcal Scalded Skin Syndrome Caused by Staphylococcus aureus, it’s a variant of bullous impetigo:Epidermal necrosis caused by bacterial exotoxins, resulting in the epithelial layer peeling off in large, sheetlike pieces; mimics scalded-skin thermal burn. This serious infection is more commonly seen in children and usually begins in the intertriginous areas. 3. Cellulitis Cellulitis is an acute infection as a result of bacterial entry via breaches in the skin barrier. As the bacteria enter the subcutaneous tissues, their toxins are released which causes an inflammatory response.  Cellulitis and erysipelas is almost always a unilateral infection with the most common site of infection being the lower extremities.  Cellulitis involves the deeper dermis and subcutaneous fat.  Cellulitis is observed most frequently among middle-aged individuals and older adults.  The vast majority of pathogens associated with cellulitis are from either Streptococcus or Staphlococcus bacteria. The most common are beta-hemolytic streptococci (groups A, B, C, G, and F), and S. aureus (gram +)  Both erysipelas and cellulitis manifest with areas of skin erythema, edema, warmth and pain. Fever may be present. Additional manifestations of cellulitis and erysipelas include lymphangitis and inflammation of regional lymph nodes. Edema surrounding the hair follicles may lead to dimpling in the skin, creating an appearance reminiscent of an orange peel texture called "peau d'orange".  Cellulitis may present with or without purulence  patients with cellulitis tend to have a more indolent course with development of localized symptoms over a few days.  Many patients with cellulitis have underlying such as tinea pedis, lymphedema, and chronic venous insufficiency. In such patients, treatment should be directed at both the infection and the predisposing condition if modifiable.  Patients with cellulitis or erysipelas in the absence of abscess or purulent drainage should be managed with empiric antibiotic therapy. Patients with drainable abscess should undergo incision and drainage. I. Describe an appropriate empiric antibiotic treatment plan for cellulitis  should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin-susceptible Staphylococcus aureus (MSSA) with: • Cephalexin 500 mg four times daily (alternative for mild penicillin allergy) • Clindamycin 300 mg to 450 mg four times daily (alternative for severe penicillin allergy)  Good choices for uncomplicated cases of cellulitis that are not associated with human or animal bites include dicloxacillin or cephalexin for 10 to 14 days.  If pt has severe PCN allergy rx erythromycin  If caused by animal or human bite: amoxicillin-clavulanic acid (augmentin) for 2 weeks The coverage for MRSA is achieved by adding to amoxicillin one of the following: Bactrim DS twice daily Doxycycline 100 mg twice daily Minocycline 200 mg orally once, then 100 mg orally every 12 hours If clindamycin is used, no additional MRSA coverage is needed.